As US FDA Commissioner Scott Gottlieb has touted the agency’s commitment to promoting the development of new opioid use disorder medications, the agency is likely to approve two new subcutaneous, long-acting buprenorphine treatments that have been billed as formulations designed to improve adherence and reduce abuse.
The Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee recently convened in back-to-back joint sessions on...




